Cardinale Goldstein*
Anthracyclines are a class of chemotherapy drugs widely used in cancer treatment. Despite their efficacy, anthracyclines are associated with a significant risk of cardiotoxicity, which can lead to heart failure. Identifying genetic signatures associated with Anthracycline-Induced Cardiotoxicity (AIC) is crucial for predicting which patients are at higher risk and for developing preventive strategies. Mid-level molecular phenotypes, which encompass changes in gene expression, protein levels, and metabolite concentrations, offer a promising approach for identifying these genetic signatures. This review discusses the integration of mid-level molecular phenotypes with genetic data to uncover biomarkers of AIC hazard. We explore the current methodologies, highlight key findings, and propose future directions for research in this field.
ఈ కథనాన్ని భాగస్వామ్యం చేయండి
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 